Atara Biotherapeutics, Inc. (ATRA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-19

Key Insights

Panacea Innovation Ltd, a 10% owner of Atara Biotherapeutics, Inc. (ATRA), has exercised 259,163 warrants for the company's common stock at an exercise price of $0.0001 per share.
James Huang, who is the sole owner of Panacea Innovation Ltd, is also a director of Atara Biotherapeutics and may be deemed to share beneficial ownership of the securities held by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P.
The insider transactions indicate Panacea Innovation Ltd's continued confidence in Atara Biotherapeutics, as the entity has increased its stake in the company through the warrant exercise.

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-14

Panacea Innovation Ltd, a 10% owner, sold 80,554 shares of Atara Biotherapeutics, Inc. (ATRA) at an average price of $6.0707 per share. This suggests some reduction in their ownership stake in the company.
James Huang, the sole owner of Panacea Innovation Ltd, is also a director and 10% owner of Atara Biotherapeutics, indicating strong ties between the reporting persons and the issuer.
The filing also shows that Panacea Opportunity Fund I, L.P., another entity associated with the reporting persons, owns an additional 48,736 shares of Atara Biotherapeutics.

Other reports for Atara Biotherapeutics, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.